SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is experiencing a volatile trading session following its WWDC keynote, as investors react to new Siri AI features and an artificial intelligence partnership with Google. While some traders are focused on a typical 'sell the news' price decline, the community is actively debating the company's competitive standing in the AI landscape compared to its peers.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending as investors digest a major 210 MW lease agreement at its Delta Forge 2 campus, a development that continues to drive optimism around the company's AI Factory franchise model and its ability to secure long-term revenue with hyperscalers. While the community remains highly bullish on the firm's expansion pace and infrastructure execution, recent price action has triggered intense debate between those treating current volatility as a strategic buying opportunity and others wary of broader sector valuation concerns.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is attracting significant investor attention as the community anticipates imminent 52-week clinical data, which is widely viewed as a pivotal catalyst for a potential M&A event. Traders are actively discussing the stock's positioning ahead of major industry conferences, with many speculating that strong data could trigger a bidding war among major pharmaceutical suitors.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis

Trulieve Cannabis is trending as investors rally ahead of the company's highly anticipated NYSE uplisting scheduled for June 10th. The community is focused on the potential for increased institutional inflows, while debates persist over market volatility, regulatory risks, and the company's strategic position as a leader in the U.S. medical cannabis market.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors react to a flurry of conflicting sentiment, including reports of aggressive shareholder outreach ahead of the upcoming board vote and active discussions surrounding the potential impact of pending proxy advisor recommendations. The community remains deeply divided, balancing high-conviction bullishness regarding the company's proprietary pipeline and vaccine assets against significant frustration over management's communication strategy and executive compensation proposals.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is experiencing significant downward pressure as investors rotate capital ahead of an anticipated major IPO, leading to heavy volatility and active discussions about whether this decline is a temporary consolidation or a sign of a deeper correction. Despite the price action, long-term investors remain focused on the company's aggressive infrastructure expansion and strategic position in the AI compute market, viewing current pullbacks as potential buying opportunities.

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.

Tango Therapeutics Inc

Tango Therapeutics is trending as investors react to clinical updates on its PRMT5 inhibitor program, balancing excitement over a new brain-penetrant candidate and upcoming combination trials with concerns regarding the discontinuation of earlier assets. The community is actively debating the company's long-term potential, with bulls citing a deep institutional pipeline and potential buyout value, while skeptics focus on the recent price volatility and the dilution risks associated with financing clinical milestones.

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

Structure Therapeutics (GPCR) is trending following positive Phase 2 obesity trial data, which demonstrated strong, durable weight loss and a competitive tolerability profile, fueling significant investor interest and M&A speculation. Community discussions are heavily focused on the stock's best-in-class potential in the small-molecule GLP-1 space, comparing its growth prospects and takeout valuation potential against other obesity-focused biotech peers.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is currently trending due to its recent recommendation for European approval of the oral Wegovy tablet, positioning the company as the first to offer an oral weight-loss GLP-1 in the region. Community discussions remain highly polarized, with many investors debating the long-term competitive landscape against Eli Lilly's injectable pipeline and focusing on the pill's growth metrics in the U.S.

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in Brisbane, CA.

Nurix Therapeutics Inc

Nurix Therapeutics is currently in the spotlight following the announcement of a multibillion-dollar collaboration with Roche to develop a blood cancer drug, a move seen by the community as major validation for their targeted protein degradation platform. While some analysts have adjusted their price targets, investors are actively debating the long-term potential of this deal, with many focusing on the bolstered cash position and the reduction of future development risk.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Midland States Bancorp (NASDAQ:MSBI) Board of Directors Approves Share Buyback Plan

Midland States Bancorp (NASDAQ:MSBI - Get Free Report) announced that its board has initiated a stock repurchase program on Wednesday, May 6th, RTT News reports. The company plans to repurchase $45.00 million in outstanding shares. This repurchase authorization authorizes the financial services...

Midland States Bancorp (NASDAQ:MSBI) Reaches New 1-Year High  - What's Next?

Midland States Bancorp (NASDAQ:MSBI) Reaches New 1-Year High - Here's Why...

Midland States Bancorp (NASDAQ:MSBI) Raised to Strong-Buy at Zacks Research

Zacks Research upgraded shares of Midland States Bancorp from a "hold" rating to a "strong-buy" rating in a research report on Tuesday...

Midland States Bancorp (MSBI) Is Up 5.09% in One Week: What You Should Know 

Does Midland States Bancorp (MSBI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Midland States Bancorp (MSBI) Moves to Strong Buy: Rationale Behind the Upgrade

Midland States Bancorp (MSBI) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Should Value Investors Buy Midland States Bancorp (MSBI) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Midland States Bancorp (NASDAQ:MSBI) Sets New 52-Week High  - Still a Buy?

Midland States Bancorp (NASDAQ:MSBI) Sets New 1-Year High - Should You Buy...

Midland States Bancorp (NASDAQ:MSBI) Shares Gap Up After Strong Earnings

Midland States Bancorp (NASDAQ:MSBI) Shares Gap Up After Strong Earnings...

Midland States Bancorp (MSBI) Reports Q1 Earnings: What Key Metrics Have to Say

The headline numbers for Midland States Bancorp (MSBI) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Midland States Bancorp (MSBI) Tops Q1 Earnings and Revenue Estimates

Midland States Bancorp (MSBI) delivered earnings and revenue surprises of +32.77% and +5.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Midland States Bancorp, Inc. is a bank holding company, which engages in the provision of commercial and consumer banking products and services. It operates through the following segments: Banking, Wealth Management, and Corporate. The Banking segment offers financial products and services such as loans, mortgage loan sales and servicing, letters of credit, deposit products, merchant services, and corporate treasury management services. The Wealth Management segment consists of trust and fiduciary services, brokerage, and retirement planning services. The Corporate segment refers to the holding company financing and investment activities, administrative expenses, as well as the elimination of intercompany transactions. The company was founded in 1988 and is headquartered in Effingham, IL.

MSBIMidland States Bancorp Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MSBI News